Compare UG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | NNVC |
|---|---|---|
| Founded | 1942 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 37.9M |
| IPO Year | 1995 | 2008 |
| Metric | UG | NNVC |
|---|---|---|
| Price | $7.73 | $1.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 349.7K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.58 | $0.85 |
| 52 Week High | $9.78 | $2.23 |
| Indicator | UG | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 75.49 | 61.20 |
| Support Level | $6.85 | $1.18 |
| Resistance Level | N/A | $1.90 |
| Average True Range (ATR) | 0.16 | 0.15 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 83.32 | 78.18 |
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.